A former senior executive of Bristol-Myers Squibb, Andrew Bodnar, has pleaded guilty for his role in the US drug major's dishonest dealings with the federal government relating to a patent deal involving Plavix (clopidogrel), a blockbuster blood-thinner developed with Sanofi-Aventis.
The plea follows B-MS' June 11, 2007, agreement to plead guilty and pay a $1.0 million criminal fine for misleading the US government about a deal that threatened to reduce competition and could have lowered the cost of the drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze